EPD’s Cardiac Mapping and Navigation System received CE mark approval. The system helps electrophysiologists navigate the heart by generating an accurate 3D map, while imaging and pinpointing the exact location and orientation of catheters in the heart during diagnostic and therapeutic procedures for cardiac arrhythmias.Read Story
Results from EPD’s DURABLE-I clinical trial, whose principal investigator is Professor Evgeny A Pokushalov, were presented for the first time at the 2017 AF Symposium by Professor Karl-Heinz Kuck, Head of the Department of Cardiology at the Asklepios Klinik in Hamburg, Germany. The presentation, “DURABLE-I Study: Real-time gap detection during AF ablation using dielectric sensing”, […]Read Story
EPD has completed its first human procedure, having successfully tested its revolutionary D700 Dielectric Sensing System at the Meshalkin State Research Institute of Circulation Pathology in Novosibirsk, Russia, headed by Professor Evgeny Pokushalov. The EPD D700 System employs dielectric sensing for guided personalized intra-cardiac navigation, and provides electrode-tissue contact quality, real-time lesion assessment and gap […]Read Story
Prof. Shlomo Ben-Haim, Founder of Hobart Group, authored “How Innovation Can Unleash Tremendous Growth in the $3.4 Billion AF Ablation Market”, published…Read Story
EPD will present its novel real-time D700 tissue characterization technology for permanent transmural ablation at the upcoming 13th International Dead Sea Symposium (IDSS)…Read Story
An editorial written by Mattias Duytschaever, Philippe Taghji and Rene Tavernier referring to the seminal paper ‘EFFICAS II: optimization of catheter…Read Story
EPD presented its proprietary catheter-based cardiac ablation platform in a private setting at the annual Heart Rhythm Society (HRS) conference in Boston…Read Story
EPD has been successful in securing further funding to commercialize its technology…Read Story
Results from the Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE) trial were presented…Read Story
Atrial fibrillation (AF) is an abnormal heart rhythm which is characterized by irregular and rapid beating. As the most common arrhythmia, it affects about 3% of the population in North America and Europe and is the second leading cause of stroke.
EPD Solutions (EPD), a member of the Hobart Group companies, is dedicated to improving the efficacy and efficiency of minimally invasive catheter-based procedures performed to treat cardiac arrhythmias. For more information, please visit www.epd-medical.com.
The Hobart Group accelerates ideas and develops and commercializes medical technologies, targeting top healthcare markets with significant unmet needs. Its growing portfolio of companies covers the fields of cardiology, diabetes, oncology, neurology and rehabilitation. Together, Hobart Group companies employ over 200 scientists, engineers, regulatory and business experts across four continents, benefitting from the group’s financial strength, clinical expertise and extensive international market knowledge across Europe, the US and Asia. For more information please visit www.hobart-group.com.